Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity

被引:21
|
作者
Fournier, B
Hooper, DC
机构
[1] Harvard Univ, Div Infect Dis, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA
[2] Harvard Univ, Med Serv, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA
关键词
D O I
10.1128/AAC.42.8.2109
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The grlA genes of Staphylococcus aureus ISP794 (wild type), MT5224c4 (grlA [Phe-80]), MT5224c2 (grlA [Pro-116]), and MT111 (grlA [Glu-116]) were cloned in pSK950, a shuttle vector, and introduced into S, aureus strains derived from strain RN4220. The mutations at position 116 of GrlA (Ala-->Pro or Glu) caused an increase in the level of fluoroquinolone resistance and a decrease in the level of coumarin susceptibility, whereas the mutation at position 80 (Ser-->Phe) caused only an increase in the level of fluoroquinolone resistance. In multicopy alleles, both types of mutations were codominant for fluoroquinolone resistance, and mutations at position 116 were also codominant for coumarin resistance.
引用
收藏
页码:2109 / 2112
页数:4
相关论文
共 50 条
  • [21] Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus
    Tanaka, M
    Onodera, Y
    Uchida, Y
    Sato, K
    Hayakawa, I
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2362 - 2366
  • [22] Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus
    Takahashi, H
    Kikuchi, T
    Shoji, S
    Fujimura, S
    Lutfor, AB
    Tokue, Y
    Nukiwa, T
    Watanabe, A
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (01) : 49 - 57
  • [23] Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV
    Yun, HJ
    Min, YH
    Jo, YW
    Shim, MJ
    Choi, EC
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (04) : 334 - 337
  • [24] ANALYSIS OF GYRA AND GRLA MUTATIONS IN STEPWISE-SELECTED CIPROFLOXACIN-RESISTANT MUTANTS OF STAPHYLOCOCCUS-AUREUS
    FERRERO, L
    CAMERON, B
    CROUZET, J
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) : 1554 - 1558
  • [25] Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance
    Low, DE
    Muller, M
    Duncan, CL
    Willey, BM
    de Azavedo, JC
    McGeer, A
    Kreiswirth, BN
    Pong-Porter, S
    Bast, DJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 1119 - 1121
  • [26] QUINOLONE RESISTANCE MUTATIONS IN THE DNA GYRASE GYRA AND GYRB GENES OF STAPHYLOCOCCUS-AUREUS
    ITO, H
    YOSHIDA, H
    BOGAKISHONAI, M
    NIGA, T
    HATTORI, H
    NAKAMURA, S
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (09) : 2014 - 2023
  • [27] DNA Gyrase and Topoisomerase IV Mutations in Quinolone-Resistant Flavobacterium psychrophilum Isolated from Diseased Salmonids in Norway
    Shah, Syed Q. A.
    Nilsen, Hanne
    Bottolfsen, Kirsten
    Colquhoun, Duncan J.
    Sorum, Henning
    MICROBIAL DRUG RESISTANCE, 2012, 18 (02) : 207 - 214
  • [28] Action of quinolones against Staphylococcus aureus topoisomerase IV:: Basis for DNA cleavage enhancement
    Anderson, VE
    Zaniewski, RP
    Kaczmarek, FS
    Gootz, TD
    Osheroff, N
    BIOCHEMISTRY, 2000, 39 (10) : 2726 - 2732
  • [29] Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus:: effects of the mutations on fluoroquinolone MICs
    Horii, T
    Suzuki, Y
    Monji, A
    Morita, M
    Muramatsu, H
    Kondo, Y
    Doi, M
    Takeshita, A
    Kanno, T
    Maekawa, M
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 46 (02) : 139 - 145
  • [30] Quinolone Alkaloids from Fructus Euodiae Show Activity Against Methicillin-Resistant Staphylococcus aureus
    Pan, Xiaobei
    Bligh, S. W. Annie
    Smith, Eileen
    PHYTOTHERAPY RESEARCH, 2014, 28 (02) : 305 - 307